$0.20 EPS Expected for Crawford & Company (CRD.B); Collegium Pharmaceutical (COLL) Shorts Increased By 10.02%

July 26, 2017 - By Dolores Ford

Analysts expect Crawford & Company (NYSE:CRD.B) to report $0.20 EPS on August, 14.They anticipate $0.01 EPS change or 5.26% from last quarter’s $0.19 EPS. CRD_B’s profit would be $10.19 million giving it 11.24 P/E if the $0.20 EPS is correct. After having $0.13 EPS previously, Crawford & Company’s analysts see 53.85% EPS growth. About 9,078 shares traded. Crawford & Company (NYSE:CRD.B) has risen 18.83% since July 26, 2016 and is uptrending. It has outperformed by 2.13% the S&P500.

Collegium Pharmaceutical Incorporated (NASDAQ:COLL) had an increase of 10.02% in short interest. COLL’s SI was 6.25 million shares in July as released by FINRA. Its up 10.02% from 5.68M shares previously. With 477,000 avg volume, 13 days are for Collegium Pharmaceutical Incorporated (NASDAQ:COLL)’s short sellers to cover COLL’s short positions. The SI to Collegium Pharmaceutical Incorporated’s float is 32.82%. About 318,929 shares traded. Collegium Pharmaceutical Inc (NASDAQ:COLL) has declined 44.24% since July 26, 2016 and is downtrending. It has underperformed by 60.94% the S&P500.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The company has market cap of $373.68 million. The Firm is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. It currently has negative earnings. The Company’s products include Xtampza ER and ONSOLIS.

Among 6 analysts covering Collegium Pharmaceutical Inc (NASDAQ:COLL), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Collegium Pharmaceutical Inc had 8 analyst reports since February 19, 2016 according to SRatingsIntel. The stock of Collegium Pharmaceutical Inc (NASDAQ:COLL) earned “Buy” rating by Jefferies on Monday, June 12. William Blair initiated Collegium Pharmaceutical Inc (NASDAQ:COLL) on Friday, February 19 with “Outperform” rating. The company was maintained on Friday, July 14 by Jefferies. The stock of Collegium Pharmaceutical Inc (NASDAQ:COLL) has “Buy” rating given on Friday, June 9 by Janney Capital. Gabelli initiated it with “Buy” rating and $25 target in Tuesday, September 13 report. Needham maintained the stock with “Buy” rating in Friday, June 9 report. The company was maintained on Tuesday, July 25 by Piper Jaffray.

Crawford & Company is an independent well-known provider of claims management solutions to insurance and self-insured entities. The company has market cap of $458.22 million. The Company’s Crawford Solution offers claims services, business process outsourcing and consulting services for various product lines, including property and casualty claims management; workers’ compensation claims and medical management, and legal settlement administration. It has a 14.53 P/E ratio. Crawford conducts its activities through four divisions: U.S.